Search
for
Sort by
Research 91–120 of 103
- Hair regeneration using microneedle-assisted human basic fibroblast growth factor
- Treatment Patterns and Unmet Needs in the Management of Alopecia Areata: Results of a Physician’s Survey in the Middle East
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- Real World Evidence in Alopecia Areata: Current Management, Emerging Therapies and Future Challenges – A Narrative Review
- Alopecia areata and pattern hair loss (androgenetic alopecia) on social media – Current public interest trends and cross‐sectional analysis of YouTube and TikTok contents
- Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients
- Effects of Allium hookeri Extracts on Hair-Inductive and Anti-Oxidative Properties in Human Dermal Papilla Cells
- COMPARISON OF EFFICACY OF BARICITINIB VERSUS METHOTREXATE THERAPY IN THE TREATMENT OF SEVERE ALOPECIA AREATA
- Comparison of Current International Guidelines for the Management of Alopecia Areata—Comprehensive Review
- Evaluation of Efficacy of Water-Soluble Fraction of Rhus semialata Gall Extract and Penta-O-Galloyl-β-D-Glucose on Mitigation of Hair Loss: An In Vitro and Randomized Double-Blind Placebo-Controlled Clinical Study
- Effect of Scenedesmus deserticola JD052 Extracts on Hair Inductivity by Regulating the AKT and GSK3β/β-Catenin Signaling Pathways in Human Dermal Papilla Cells
- Evaluation of Hair Growth Promoting Activity of Standardized Soybean Extract on Testosterone-Induced Alopecia
- Discovery of a novel and highly selective JAK3 inhibitor as a potent hair growth promoter
- Baricitinib (Olumiant)
- Baricitinib (Olumiant)
- Olumiant® (Baricitinib)-A Newly Approved Janus Kinase Inhibitor for the Treatment of Alopecia Areata.
- Efficacy of JAK 1/2 inhibition in the treatment of diffuse non-scarring alopecia due to systemic lupus erythematosus
- Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase‐4 inhibitors
- Shedding light on therapeutics in alopecia and their relevance to COVID-19
- Alopecia Areata: Case report and review of pathophysiology and treatment with Jak inhibitors
- European expert consensus statement on the systemic treatment of alopecia areata
- Good efficacy achieved by baricitinib in the treatment of anti-MDA5 antibody-positive dermatomyositis with alopecia areata
- Baricitinib as the first systemic treatment for severe alopecia areata
- Perifolliculitis capitis abscedens et suffodiens treatment with tumor necrosis factor inhibitors and baricitinib: A case report and literature review
- Alopecia areata: from pathophysiology to therapeutic innovation
- Alopecia areata. Diagnostic and therapeutic recommendations of the Polish Society of Dermatology. Part 2: Treatment
- Perspectives of Chinese Adult Patients with Alopecia Areata on Janus Kinase Inhibitors Therapy: A Qualitative Analysis Based on Social Media Platforms
- 52709 Patient-Reported Outcomes for Scalp, Eyebrow and Eyelash Hair Loss in Patients with Severe Alopecia Areata Treated with Baricitinib: 152 Week Results from two Phase 3 Clinical Trials
- JAK Inhibitor Baricitinib in the Treatment of Oral Lichen Planus: A Case Report
- Agreement Between Patient and Physician Assessment of Eyebrow and Eyelash Hair Loss in Two Phase 3 Trials Evaluating Baricitinib in Patients with Severe Alopecia Areata